End Points in Hospital-Acquired Pneumonia and/or Ventilator-Associated Pneumonia Clinical Trials: Food and Drug Administration Perspective
Clicks: 117
ID: 271071
2010
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
117 views
29 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #676 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract. Identification of reliable, reproducible, and precise end points for future studies of hospital-acquired and ventilator-associated pneumonia is of par
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (20 words).
Try re-searching for a better abstract.
| Reference Key |
a.2010clinicalend
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Laessig, Katherine A.; |
| Journal | clinical infectious diseases |
| Year | 2010 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.